Literature DB >> 30806965

Authors' Reply to Tsivgoulis et al.: "Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A likelihood to Achieve No Evidence of Disease Activity or Harm Analysis".

Dimitrios Papadopoulos1, Dimos-Dimitrios D Mitsikostas2.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 30806965     DOI： 10.1007/s40263-019-00616-4

Source DB:  PubMed          Journal:  CNS Drugs        ISSN： 1172-7047            Impact factor:   5.749


× No keyword cloud information.
  5 in total

Review 1.  Communicating the benefits and harms of treatments.

Authors:  A K Akobeng
Journal:  Arch Dis Child       Date:  2008-05-02       Impact factor: 3.791

Review 2.  Confidence intervals for the number needed to treat.

Authors:  D G Altman
Journal:  BMJ       Date:  1998-11-07

3.  Comment on: "Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis".

Authors:  Georgios Tsivgoulis; Lina Palaiodimou; Aristeidis H Katsanos; Konstantinos Voumvourakis; Georgios M Hadjigeorgiou; Ioannis Heliopoulos; Theodore Karapanayiotides; Panagiotis Papathanasopoulos; Constantinos Kilidireas; Nikolaos Grigoriadis
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

4.  Correction to: Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.

Authors:  Dimitrios Papadopoulos; Dimos-Dimitrios D Mitsikostas
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

5.  Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.

Authors:  Dimitrios Papadopoulos; Dimos-Dimitrios D Mitsikostas
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.